Patrick Burnett News Today

Frazier Life Sciences Management L.P. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,764,232 shares of the company’s stock after buying an additional 80,000 shares during […]

Frazier Life Sciences Management L.P. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,764,232 shares of the company’s stock after buying an additional 80,000 shares during […]

Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.65. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript February 27, 2024 Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.65. Arcutis Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]

Novel steroid-free topical foam effectively controls seborrheic dermatitisOnce-daily ZORYVE® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

In this subgroup analysis data shown at Winter Clinical, findings indicated IGA success with topical roflumilast foam among seborrheic dermatitis patients.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of Arcutis Biotherapeutics stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.75, for a total transaction of $201,250.00. Following the completion of the sale, the insider now owns 209,793 shares of the […]

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.75, for a total value of $201,250.00. Following the sale, the insider now directly owns 209,793 shares of the company’s […]

The new nonsteroidal drug, Zoryve, can relieve itching and swelling on the skin and scalp.